Pulmonary Alveolar Proteinosis
Pulmonary Alveolar Proteinosis (PAP) is a rare lung disease where a protein-rich substance builds up in the air sacs of the lungs, leading to breathing difficulties and reduced oxygen levels in the blood.
Inhaled Molgramostim for Pediatric Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
We are studying the effects of inhaled molgramostim in children and teens with aPAP. The goal is to see if it is safe and effective for improving their condition.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 6 and 17 years old?
- Do you have a history of pulmonary alveolar proteinosis (a lung condition)?
- Have you had a positive test for anti-GM-CSF autoantibodies?
- Have you had any treatment for your lung condition in the past month?
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Compensan Retard
Lacedor
Morfin Abcur
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Ludwig-Maximilians-Universitaet Muenchen
01:Dr. von Haunersches Kinderspital - Kinderklinik und Kinderpoliklinik
Munich, Germany
Sponsor: Savara ApS
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.